Search

everythinglearnresearchcommunity

for

Search:↓

The current understanding of frontal fibrosing alopecia involves immune, genetic, hormonal factors, and possibly environmental triggers, but more research is needed for effective treatments.

Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.

Reduced SIRT1 in hair cells may cause alopecia areata by triggering immune responses.

Both Th1 and Th2 immune responses are increased in alopecia areata, with Th2 response more strongly linked to how severe the disease is.

Hair growth phase in mice weakens certain immune responses.

Dupilumab may worsen hair loss in patients with alopecia areata.

People with alopecia areata are more likely to have other immune-related conditions.

Certain immune cells contribute to severe hair loss in chronic alopecia areata, with Th17 cells possibly having a bigger impact than cytotoxic T cells.

New treatments for seborrheic dermatitis show promise for difficult cases.

Certain immune-related proteins are higher in people with alopecia and their healthy relatives, hinting at a genetic link.

Canine pemphigus foliaceus involves significant immune activity and shares similarities with human pemphigus.

Controlled delivery of specific RNA and IL-4 restored hair growth in mice with autoimmune alopecia.

JAK inhibitors are effective for treating moderate-to-severe alopecia areata.

RXRα is crucial for proper immune response and links diet to immune function.

Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.

PCOS involves immune system issues and inflammation, possibly leading to autoimmune diseases.

EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.

Lower CD200R1 on certain immune cells is linked to more severe rheumatoid arthritis and immune imbalance.

Genetically at-risk healthy people show similar immune issues as those with Pemphigus vulgaris or Alopecia areata.

The study identified key immune cell differences between mild and severe alopecia areata.

A vitamin D receptor mutation causes rickets and affects immune responses.

Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.

Upadacitinib improved multiple immune-related conditions in one patient.

The new skin-targeted COVID-19 vaccine creates strong immune responses and could improve vaccination methods.

Atopic dermatitis and alopecia areata share immune and genetic factors, and targeted therapies may help both.

CD2 might be a new treatment target for patchy alopecia areata.

Hair follicles in nonsegmental vitiligo are better protected from immune attacks than in alopecia areata.

Alopecia areata may be treated by using EGCG to balance immune cells and reduce inflammation.

Platelet-rich plasma might help treat eczema by reducing inflammation and repairing the skin.

Alopecia areata severity and treatment response are linked to specific cytokine levels.